ProShare Advisors LLC Sells 64,995 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

ProShare Advisors LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,266,276 shares of the biopharmaceutical company’s stock after selling 64,995 shares during the quarter. ProShare Advisors LLC owned 0.10% of Gilead Sciences worth $97,592,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Gilead Sciences by 98,797.6% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock worth $30,366,034,000 after purchasing an additional 393,607,491 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Gilead Sciences by 324.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $1,115,186,000. Moneta Group Investment Advisors LLC grew its holdings in shares of Gilead Sciences by 96,759.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after purchasing an additional 10,100,755 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Institutional investors own 82.33% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the sale, the insider now directly owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $75.21 on Monday. The company has a market capitalization of $93.71 billion, a price-to-earnings ratio of 16.19, a P/E/G ratio of 1.00 and a beta of 0.32. The firm’s 50 day simple moving average is $76.82 and its 200 day simple moving average is $77.26. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.34 and a quick ratio of 1.20. Gilead Sciences, Inc. has a fifty-two week low of $72.87 and a fifty-two week high of $89.74.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.38. The business had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. Gilead Sciences’s revenue for the quarter was up .1% on a year-over-year basis. During the same period last year, the company posted $1.90 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.76 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a $0.75 dividend. The ex-dividend date is Thursday, December 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.99%. Gilead Sciences’s dividend payout ratio is 64.38%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GILD shares. UBS Group lowered their target price on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. Morgan Stanley upped their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Friday, August 4th. Leerink Partnrs reiterated a “market perform” rating on shares of Gilead Sciences in a research report on Wednesday, October 11th. Bank of America upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $88.00 to $95.00 in a research report on Friday, September 8th. Finally, HSBC started coverage on shares of Gilead Sciences in a research report on Wednesday, September 6th. They set a “reduce” rating and a $71.00 price target on the stock. One analyst has rated the stock with a sell rating, ten have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $88.22.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.